Quanterix Co. (NASDAQ:QTRX) Shares Purchased by Barclays PLC

Barclays PLC raised its holdings in Quanterix Co. (NASDAQ:QTRX) by 42.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 146,248 shares of the company’s stock after acquiring an additional 43,447 shares during the period. Barclays PLC owned approximately 0.38% of Quanterix worth $1,896,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Pier Capital LLC increased its holdings in shares of Quanterix by 23.5% in the third quarter. Pier Capital LLC now owns 511,798 shares of the company’s stock valued at $6,633,000 after purchasing an additional 97,256 shares during the last quarter. State Street Corp grew its holdings in Quanterix by 2.2% in the 3rd quarter. State Street Corp now owns 836,443 shares of the company’s stock valued at $10,840,000 after buying an additional 18,050 shares in the last quarter. Portolan Capital Management LLC increased its stake in shares of Quanterix by 31.4% in the 3rd quarter. Portolan Capital Management LLC now owns 2,520,686 shares of the company’s stock worth $32,668,000 after acquiring an additional 602,656 shares during the last quarter. FMR LLC raised its holdings in shares of Quanterix by 112.6% during the 3rd quarter. FMR LLC now owns 30,242 shares of the company’s stock worth $392,000 after acquiring an additional 16,020 shares during the period. Finally, Algert Global LLC boosted its position in shares of Quanterix by 75.9% during the 3rd quarter. Algert Global LLC now owns 137,833 shares of the company’s stock valued at $1,786,000 after acquiring an additional 59,496 shares during the last quarter. 86.48% of the stock is owned by hedge funds and other institutional investors.

Quanterix Stock Up 5.2 %

NASDAQ:QTRX opened at $11.07 on Friday. The company has a market capitalization of $424.86 million, a P/E ratio of -10.54 and a beta of 1.30. Quanterix Co. has a 52 week low of $9.87 and a 52 week high of $29.70. The stock’s fifty day moving average is $12.29 and its two-hundred day moving average is $12.95.

Analyst Upgrades and Downgrades

Separately, TD Cowen lifted their target price on shares of Quanterix from $13.50 to $16.00 and gave the stock a “hold” rating in a research note on Wednesday, November 13th.

Quanterix Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.